Diet Polyphenol Curcumin Stimulates Hepatic Fgf21 Production and Restores Its Sensitivity in High-Fat-Diet–Fed Male Mice
暂无分享,去创建一个
T. Jin | Ling Liu | J. Weng | I. McGilvray | Xuezhong Ma | J. Manuel | C. Cummins | W. Shao | Rucha A Patel | Kejing Zeng | L. Tian | Zhuolun Song
[1] M. Beekman,et al. Fibroblast growth factor 21 reflects liver fat accumulation and dysregulation of signalling pathways in the liver of C57BL/6J mice , 2016, Scientific Reports.
[2] C. Musante,et al. PF-05231023, a long-acting FGF21 analogue, decreases body weight by reduction of food intake in non-human primates , 2016, Journal of Pharmacokinetics and Pharmacodynamics.
[3] P. Leung,et al. Fibroblast Growth Factor 21 As an Emerging Therapeutic Target for Type 2 Diabetes Mellitus , 2016, Medicinal research reviews.
[4] Jeffrey R. Chabot,et al. A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects. , 2016, Cell metabolism.
[5] F. Villarroya,et al. Dietary Betaine Supplementation Increases Fgf21 Levels to Improve Glucose Homeostasis and Reduce Hepatic Lipid Accumulation in Mice , 2016, Diabetes.
[6] R. DiMarchi,et al. FGF21 Revolutions: Recent Advances Illuminating FGF21 Biology and Medicinal Properties , 2015, Trends in Endocrinology & Metabolism.
[7] I. G. Fantus,et al. Short-Term Curcumin Gavage Sensitizes Insulin Signaling in Dexamethasone-Treated C57BL/6 Mice. , 2015, The Journal of nutrition.
[8] Xiaokun Li,et al. Additive protection by LDR and FGF21 treatment against diabetic nephropathy in type 2 diabetes model. , 2015, American journal of physiology. Endocrinology and metabolism.
[9] Yuan Zhang,et al. Role of fibroblast growth factor 21 in the early stage of NASH induced by methionine- and choline-deficient diet. , 2015, Biochimica et biophysica acta.
[10] N. Stefan,et al. Fibroblast growth factor 21 is elevated in metabolically unhealthy obesity and affects lipid deposition, adipogenesis, and adipokine secretion of human abdominal subcutaneous adipocytes , 2015, Molecular metabolism.
[11] C. Morrison,et al. Protein-dependent regulation of feeding and metabolism , 2015, Trends in Endocrinology & Metabolism.
[12] Yuan Zhang,et al. Glucocorticoids regulate the metabolic hormone FGF21 in a feed-forward loop. , 2015, Molecular endocrinology.
[13] A. Xu,et al. Circulating fibroblast growth factor 21 levels predict progressive kidney disease in subjects with type 2 diabetes and normoalbuminuria. , 2015, The Journal of clinical endocrinology and metabolism.
[14] T. Jin,et al. Liver-Specific Expression of Dominant-Negative Transcription Factor 7-Like 2 Causes Progressive Impairment in Glucose Homeostasis , 2015, Diabetes.
[15] S. Kliewer,et al. Circulating FGF21 Is Liver Derived and Enhances Glucose Uptake During Refeeding and Overfeeding , 2014, Diabetes.
[16] D. Schuppan,et al. Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. , 2014, Gastroenterology.
[17] Xiaokun Li,et al. Inhibition of JNK Phosphorylation by a Novel Curcumin Analog Prevents High Glucose–Induced Inflammation and Apoptosis in Cardiomyocytes and the Development of Diabetic Cardiomyopathy , 2014, Diabetes.
[18] G. Bray,et al. FGF21 is an endocrine signal of protein restriction. , 2014, The Journal of clinical investigation.
[19] H. Shulha,et al. The PPARα-FGF21 hormone axis contributes to metabolic regulation by the hepatic JNK signaling pathway. , 2014, Cell metabolism.
[20] T. Jin,et al. p21-Activated protein kinases and their emerging roles in glucose homeostasis. , 2014, American journal of physiology. Endocrinology and metabolism.
[21] A. Adams,et al. Inventing new medicines: The FGF21 story☆ , 2013, Molecular metabolism.
[22] H. Fu,et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes. , 2013, Cell metabolism.
[23] Lingyun Zhu,et al. The Wnt Signaling Pathway Effector TCF7L2 Controls Gut and Brain Proglucagon Gene Expression and Glucose Homeostasis , 2013, Diabetes.
[24] T. Jin,et al. The Wnt signaling pathway effector TCF7L2 is upregulated by insulin and represses hepatic gluconeogenesis. , 2012, American journal of physiology. Endocrinology and metabolism.
[25] S. Jirawatnotai,et al. Curcumin Extract for Prevention of Type 2 Diabetes , 2012, Diabetes Care.
[26] W. Ling,et al. Curcumin attenuates Nrf2 signaling defect, oxidative stress in muscle and glucose intolerance in high fat diet-fed mice. , 2012, World journal of diabetes.
[27] I. G. Fantus,et al. Curcumin Prevents High Fat Diet Induced Insulin Resistance and Obesity via Attenuating Lipogenesis in Liver and Inflammatory Pathway in Adipocytes , 2012, PloS one.
[28] Ranjeny Thomas,et al. Targeting Curcusomes to Inflammatory Dendritic Cells Inhibits NF-κB and Improves Insulin Resistance in Obese Mice , 2011, Diabetes.
[29] A. Xu,et al. Research Design and Methods , 2005, Hormone Research in Paediatrics.
[30] I. G. Fantus,et al. Oltipraz upregulates the nuclear respiratory factor 2 alpha subunit (NRF2) antioxidant system and prevents insulin resistance and obesity induced by a high-fat diet in C57BL/6J mice , 2011, Diabetologia.
[31] A. Bookout,et al. LXRβ is required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. , 2011, The Journal of clinical investigation.
[32] Jian Xiao,et al. Serum Levels of FGF-21 Are Increased in Coronary Heart Disease Patients and Are Independently Associated with Adverse Lipid Profile , 2010, PloS one.
[33] A. Awad,et al. Curcumin and obesity: evidence and mechanisms. , 2010, Nutrition reviews.
[34] B. Aktas,et al. Increased serum FGF21 levels in patients with nonalcoholic fatty liver disease , 2010, European journal of clinical investigation.
[35] J. Flier,et al. Obesity Is a Fibroblast Growth Factor 21 (FGF21)-Resistant State , 2010, Diabetes.
[36] M. Martínez-Chantar,et al. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. , 2010, Gastroenterology.
[37] A. Kharitonenkov. FGFs and metabolism. , 2009, Current opinion in pharmacology.
[38] T. Jin,et al. The rho guanosine 5'-triphosphatase, cell division cycle 42, is required for insulin-induced actin remodeling and glucagon-like peptide-1 secretion in the intestinal endocrine L cell. , 2009, Endocrinology.
[39] E. Maratos-Flier,et al. A very low carbohydrate ketogenic diet improves glucose tolerance in ob/ob mice independently of weight loss. , 2009, American journal of physiology. Endocrinology and metabolism.
[40] S. Kliewer,et al. FGF21 induces PGC-1α and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response , 2009, Proceedings of the National Academy of Sciences.
[41] R. DeFronzo,et al. Circulating Fibroblast Growth Factor-21 Is Elevated in Impaired Glucose Tolerance and Type 2 Diabetes and Correlates With Muscle and Hepatic Insulin Resistance , 2009, Diabetes Care.
[42] A. Pfeiffer,et al. Free Fatty Acids Link Metabolism and Regulation of the Insulin-Sensitizing Fibroblast Growth Factor-21 , 2009, Diabetes.
[43] D. Moller,et al. Fibroblast growth factor 21 corrects obesity in mice. , 2008, Endocrinology.
[44] K. Oishi,et al. Circadian expression of FGF21 is induced by PPARα activation in the mouse liver , 2008, FEBS letters.
[45] M. Eriksson,et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. , 2008, Cell metabolism.
[46] Kenny K. Wong,et al. Adipose Fibroblast Growth Factor 21 Is Up-Regulated by Peroxisome Proliferator-Activated Receptor γ and Altered Metabolic States , 2008, Molecular Pharmacology.
[47] R. Leibel,et al. Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity. , 2008, Endocrinology.
[48] S. Chung,et al. Aldose Reductase Regulates Hepatic Peroxisome Proliferator-activated Receptor α Phosphorylation and Activity to Impact Lipid Homeostasis* , 2008, Journal of Biological Chemistry.
[49] Feng Liu,et al. Serum FGF21 Levels Are Increased in Obesity and Are Independently Associated With the Metabolic Syndrome in Humans , 2008, Diabetes.
[50] R. Prough,et al. Modulation of Receptor Phosphorylation Contributes to Activation of Peroxisome Proliferator Activated Receptor α by Dehydroepiandrosterone and Other Peroxisome Proliferators , 2008, Molecular Pharmacology.
[51] T. Lundåsen,et al. PPARα is a key regulator of hepatic FGF21 , 2007 .
[52] J. Flier,et al. Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states. , 2007, Cell metabolism.
[53] S. Kliewer,et al. Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. , 2007, Cell metabolism.
[54] S. Kliewer,et al. Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily Members , 2007, Molecular and Cellular Biology.
[55] Yun-Fei Chen,et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. , 2007, Endocrinology.
[56] J. Gromada,et al. FGF-21 as a novel metabolic regulator. , 2005, The Journal of clinical investigation.
[57] A. Scalbert,et al. Polyphenols and prevention of cardiovascular diseases , 2005, Current opinion in lipidology.
[58] D. Kelly,et al. Deactivation of peroxisome proliferator-activated receptor-alpha during cardiac hypertrophic growth. , 2000, The Journal of clinical investigation.
[59] B. Aggarwal,et al. Curcumin, a component of turmeric: From farm to pharmacy , 2013, BioFactors.
[60] A. Xu,et al. Distinct changes in serum fibroblast growth factor 21 levels in different subtypes of diabetes. , 2012, The Journal of clinical endocrinology and metabolism.
[61] T. Lundåsen,et al. PPARalpha is a key regulator of hepatic FGF21. , 2007, Biochemical and biophysical research communications.
[62] Gary Williamson,et al. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. , 2005, The American journal of clinical nutrition.